About Our Company

Our History


Feb.2000  Founded Renascience Inc. as an academic bio-venture company in Kanagawa, Japan
Oct.2002  Megsin project adopted as a university-launched R&D program by the Ministry of Economy, Trade and Industry (METI)
Oct.2005  PAI-1 project adopted as a university-launched R&D program by New Energy and Industrial Technology Development Organization (NEDO)
Dec.2010  Established Project PM Co., Ltd. (a special purpose company / subsidiary) and started the first phase 2 trial (investigator-initiated trial) for schizophrenia in collaboration with Tokyo Metropolitan Matsuzawa Hospital
Oct.2012  PAI-1 project adopted as an A-STEP funding program by Japan Science and Technology Agency (JST)
May.2014  Head office relocated to Chuo-ku, Tokyo
Oct.2014  PAI-1 cancer project adopted as an A-STEP funding program by Japan Science and Technology Agency (JST)
Oct.2016  License agreement with Eirion Therapeutics, Inc., USA for dermatological indications
Aug.2017  Initiated an investigator-initiated phase 2a study on CML
Nov.2017  Aging Project published in The New York Times (collaboration with Northwestern University School of Medicine)
Jan.2018  Merged Project PM Co., Ltd. Into Renascience Inc.
Jan.2018  Initiated an investigator-initiated clinical trial on ultra-fine endoscopy
Feb.2018  Raised capital through third-party stock issuance (Series A)
Mar.2018  Raised capital through third-party stock issuance (Series A)
Jun.2018  Initiated a phase 2 investigator-initiated clinical study on autism spectrum disorder with 13 centers including Tohoku University
Mar.2019  Raised capital through third-party stock issuance (Series B)
Aug.2019  Initiated a phase 2 investigator-initiated clinical study on CML
Dec.2019  Adopted as an AMED’s Cyclic Innovation for Clinical Empowerment (CiCLE) program
Dec.2019  Concluded an option agreement with ASKA Pharmaceutical Co., Ltd. for a license agreement of pyridoxamine on premenstrual syndrome / premenstrual dysphoric disorder
May.2020  License Agreement with Global Medical Device Company for Ultrafine Endoscopes
Jun.2020  Adopted as a sharing organization in an AMED’ s Research program for Emerging and Re-emerging Infectious Diseases (Ph2a)
Jul.2020  Signed an agreement with CHEST M.I., Inc. for the joint development and commercialization of respiratory AI solutions
Oct.2020  Investigator-initiated, phase 2 studies are underway in Japan, USA, and Turkey for the treatment of COVID-19 pneumonia
Dec.2020  Option Agreement with Daiichi Sankyo Co., Ltd. for the Treatment of Respiratory Diseases including COVID-19 pneumonia and other lung injuries
Mar.2021  Adopted as a sharing organization in an AMED’ s Research program for Emerging and Re-emerging Infectious Diseases (Ph2b)
May.2021  Collaboration Agreement with Nipro Corporation for the Development of Chronic Dialysis Support System using artificial intelligence (AI)
May.2021  Selected as AMED Translational Research Program, seeds C
June.2021  Initiated a phase IIb study (investigator-initiated clinical trial) for lung injury associated with novel coronavirus infection